Skip to content

Chlorhexidine and Essential Oil Mouthwashes on Human Beta-Defensin 2 (hbD2) and Kathelicidin (LL-37) Saliva Levels

The Effect of Chlorhexidine and Essential Oil Mouthwashes on Human Beta-Defensin 2 (hbD2) and Kathelicidin (LL-37) Saliva Levels

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04946617
Acronym
hbD2
Enrollment
120
Registered
2021-07-01
Start date
2021-07-20
Completion date
2021-12-20
Last updated
2021-07-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gingivitis, Mouth and Tooth Diseases, Periodontal Diseases

Keywords

Periodontitis, Gingivitis, Mouthwashes

Brief summary

Recent studies have shown that while mouthwashes exhibit antimicrobial properties against bacteria and their products, at the same time showing the cytotoxic effect on living cells in the mouth.29 To the best of our knowledge, there is no information about the toxicity effect of these two mouthwashes, which are highly preferred, on antimicrobial peptides secreted from the oral epithelium. Therefore, our aim in this study is to evaluate the effect of chlorhexidine and essential oil mouthwash on hBD2 and LL-37 in saliva.

Detailed description

Periodontal health continues with a balanced interaction of the oral microflora with the host defense line.

Interventions

DRUGundefined

Rinsing with mouthwashes

Sponsors

Istanbul Medeniyet University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
25 Years to 40 Years

Inclusion criteria

1. systemically healthy, 2. presence of ≥20 natural teeth, 3. agreement to participate in the study .

Exclusion criteria

1. known systemic illness, 2. smoking habit, 3. pregnancy/ lactation, 4. long-term use of anti-inflammatory drugs.

Design outcomes

Primary

MeasureTime frameDescription
Rate of periodontal parametres changes6 MonthsIncidence of Gingivitis

Contacts

Primary ContactMustafa C Yavuz, PhD
muscyz111@gmail.com+905056429856

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026